Salivary gland carcinomas (SGCs) are a heterogeneous group of rare head and neck cancers made of more than 20 pathologic types. Although the treatments of the early or loco-regionally advanced disease are similar across the different entities, these malignancies have variable biological characteristics and clinical behaviors. These specificities, especially the pathologic type and, when available, the molecular profile, are taken into account while choosing the treatment for the recurrent/metastatic phase. In this context, only few druggable molecular targets have been tested so far and not all are available in clinical practice. However, due to the rarity of SGCs, clinical trials are challenging to conduct, and most of the available evidence comes from retrospective studies.
As with all head and neck cancers, the clinical management of SGC patients needs to be defined at a multidisciplinary level due to the complexity of the disease and the heterogeneity of the available treatments. Therefore, also the clinical and translational research on SGC cannot disregard a multidisciplinary approach. For these reasons, this Research Topic was conceived at a multidisciplinary level, with Editors coming from different areas of clinical and scientific expertise. The goal of this Research Topic is to collect high-quality evidence produced by any of the actors playing a role in the specialistic management of SGC patients.
This Research Topic will consider for publication scientific articles reporting the results of research studies conducted in the context of diagnosis, epidemiology, treatment, or follow-up of SGC patients. It will accept prospective trials and retrospective case series, interventional and observational studies. The evidence suitable for publication may be obtained through purely preclinical, translational, clinical, bioinformatic or epidemiological studies. Independently of the type of articles and of the methodology, the overarching aim of this Research Topic on SCGs is to provide new knowledge on this often neglected field of head and neck oncology.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Salivary gland carcinomas (SGCs) are a heterogeneous group of rare head and neck cancers made of more than 20 pathologic types. Although the treatments of the early or loco-regionally advanced disease are similar across the different entities, these malignancies have variable biological characteristics and clinical behaviors. These specificities, especially the pathologic type and, when available, the molecular profile, are taken into account while choosing the treatment for the recurrent/metastatic phase. In this context, only few druggable molecular targets have been tested so far and not all are available in clinical practice. However, due to the rarity of SGCs, clinical trials are challenging to conduct, and most of the available evidence comes from retrospective studies.
As with all head and neck cancers, the clinical management of SGC patients needs to be defined at a multidisciplinary level due to the complexity of the disease and the heterogeneity of the available treatments. Therefore, also the clinical and translational research on SGC cannot disregard a multidisciplinary approach. For these reasons, this Research Topic was conceived at a multidisciplinary level, with Editors coming from different areas of clinical and scientific expertise. The goal of this Research Topic is to collect high-quality evidence produced by any of the actors playing a role in the specialistic management of SGC patients.
This Research Topic will consider for publication scientific articles reporting the results of research studies conducted in the context of diagnosis, epidemiology, treatment, or follow-up of SGC patients. It will accept prospective trials and retrospective case series, interventional and observational studies. The evidence suitable for publication may be obtained through purely preclinical, translational, clinical, bioinformatic or epidemiological studies. Independently of the type of articles and of the methodology, the overarching aim of this Research Topic on SCGs is to provide new knowledge on this often neglected field of head and neck oncology.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
